Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

Rhea-AI Summary

Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis. The company will showcase its Cardiac Recovery System® (CRS) platform, featuring the ASSURE® Wearable Cardioverter Defibrillator at booth #920.

The CRS platform aims to enhance sudden cardiac death protection by combining protective measures with actionable insights during critical heart failure recovery phases. Visitors can experience hands-on demonstrations of the platform, which focuses on strengthening patient-provider connections and supporting vulnerable patients' recovery.

News Market Reaction – KMTS

-1.99%

-1.99% Session close to close

In the Sep 25 session, KMTS declined 1.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota.

At booth #920, Kestra will feature its Cardiac Recovery System^® (CRS) platform, anchored by the ASSURE^® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery.

Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients.

“Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.”

Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy.

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

FAQ

When and where is Kestra Medical Technologies (KMTS) presenting at HFSA 2025?

Kestra will present at the HFSA Annual Scientific Meeting from September 26-29, 2025 in Minneapolis, Minnesota at booth #920. They will also participate in the Devices in Heart Failure Meeting on September 26.

What is Kestra Medical Technologies' (KMTS) Cardiac Recovery System platform?

The Cardiac Recovery System (CRS) platform is a solution that combines the ASSURE® Wearable Cardioverter Defibrillator with actionable insights to protect patients during early heart failure recovery and strengthen patient-provider connections.

Where can investors see Kestra's (KMTS) ASSURE system demonstration?

Investors and attendees can see the ASSURE system demonstration at booth #920 at the HFSA Annual Scientific Meeting and at the Devices in Heart Failure Meeting on September 26, 2025.

What is the main purpose of Kestra's (KMTS) presentation at HFSA 2025?

The main purpose is to showcase their Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator, demonstrating how it integrates into clinical workflows and supports guideline-directed medical therapy for heart failure patients.